China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Cyclically Adjusted Revenue per Share: ¥9.12 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600062 China Resources Double-Crane Pharmaceutical Co Ltd SHSE:600062
90 GF Score
Price ¥16.42
GF Value ¥18.86
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is China Resources Double-Crane Pharmaceutical Co Cyclically Adjusted Revenue per Share?

China Resources Double-Crane Pharmaceutical Co SHSE:600062 90 Cyclically Adjusted Revenue per Share is ¥9.12 as of Mar. 2026. GuruFocus rates SHSE:600062 with a GF Score™ of 90/100 and a GF Value™ of ¥18.86 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

China Resources Double-Crane Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was ¥2.708. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥9.12 for the trailing ten years ended in Mar. 2026.

During the past 12 months, China Resources Double-Crane Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 6.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 2.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 1.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of China Resources Double-Crane Pharmaceutical Co was 5.30% per year. The lowest was -1.50% per year. And the median was 2.30% per year.

As of today (2026-07-28), China Resources Double-Crane Pharmaceutical Co's current stock price is ¥16.42. China Resources Double-Crane Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ¥9.12. China Resources Double-Crane Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 1.80.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of China Resources Double-Crane Pharmaceutical Co was 4.28. The lowest was 1.41. And the median was 2.16.


China Resources Double-Crane Pharmaceutical Co  (SHSE:600062) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

China Resources Double-Crane Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=16.42/9.12
=1.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of China Resources Double-Crane Pharmaceutical Co was 4.28. The lowest was 1.41. And the median was 2.16.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


China Resources Double-Crane Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


China Resources Double-Crane Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for China Resources Double-Crane Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Resources Double-Crane Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

China Resources Double-Crane Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.85 7.88 7.97 8.40 8.97

China Resources Double-Crane Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.57 8.67 8.83 8.97 9.12

SHSE:600062 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Double-Crane Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Resources Double-Crane Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resources Double-Crane Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where China Resources Double-Crane Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


SHSE:600062
90GF Score
China Resources Double-Crane Pharmaceutical Co Ltd SHSE:600062
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Resources Double-Crane Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, China Resources Double-Crane Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.708/116.3033*116.3033
=2.708

Current CPI (Mar. 2026) = 116.3033.

China Resources Double-Crane Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.963 101.400 1.105
201609 1.248 102.400 1.417
201612 1.291 102.600 1.463
201703 1.465 103.200 1.651
201706 1.060 103.100 1.196
201709 1.610 104.100 1.799
201712 1.597 104.500 1.777
201803 2.049 105.300 2.263
201806 1.869 104.900 2.072
201809 2.129 106.600 2.323
201812 1.836 106.500 2.005
201903 2.524 107.700 2.726
201906 2.140 107.700 2.311
201909 2.436 109.800 2.580
201912 1.893 111.200 1.980
202003 2.092 112.300 2.167
202006 1.884 110.400 1.985
202009 2.135 111.700 2.223
202012 2.042 111.500 2.130
202103 2.308 112.662 2.383
202106 2.131 111.769 2.217
202109 2.152 112.215 2.230
202112 2.143 113.108 2.204
202203 2.414 114.335 2.456
202206 2.358 114.558 2.394
202209 2.148 115.339 2.166
202212 2.322 115.116 2.346
202303 2.701 115.116 2.729
202306 2.974 114.558 3.019
202309 2.550 115.339 2.571
202312 2.799 114.781 2.836
202403 3.080 115.227 3.109
202406 2.700 114.781 2.736
202409 2.542 115.785 2.553
202412 2.590 114.893 2.622
202503 2.997 115.116 3.028
202506 2.584 114.907 2.615
202509 2.439 115.471 2.457
202512 2.624 115.832 2.635
202603 2.708 116.303 2.708

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥9.12 mean?
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) has a Cyclically Adjusted Revenue per Share of ¥9.12 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors.
Is China Resources Double-Crane Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
China Resources Double-Crane Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is ¥9.12. Overall, China Resources Double-Crane Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Double-Crane Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ZTS?
China Resources Double-Crane Pharmaceutical Co's Cyclically Adjusted Revenue per Share of ¥9.12 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. China Resources Double-Crane Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is ¥9.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Double-Crane Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co (SHSE:600062) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.86, compared to a current price of ¥16.42 — trading 12.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥9.12. China Resources Double-Crane Pharmaceutical Co's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For China Resources Double-Crane Pharmaceutical Co (SHSE:600062), the current Cyclically Adjusted Revenue per Share is ¥9.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?

Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥16.42 is trading 12.9% below its estimated GF Value™ of ¥18.86. GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:600062:

  • Cyclically Adjusted Revenue per Share: ¥9.12
  • GF Value™: ¥18.86 vs. price of ¥16.42 (12.9% below fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


China Resources Double-Crane Pharmaceutical Co Business Description

Address No. 1, East Second Road, Lijing, Wangjing, Chaoyang District, Beijing, CHN, 100102
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
90GF Score

Get the complete analysis for SHSE:600062

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥16.42
Price
¥18.86
GF Value